Pharmaceuticals

NRx Pharmaceuticals Submits Two New Drug Applications for Depression Treatments NRX-101 and NRX-100

bexib
By bexib 0 Min Read

The company says that if both NRX-101 and NRX-100 are approved, it expects to generate revenue of more than $150 per NRXP share in the near future.

You Might Also Like

FDA issues complete response letter to Novo Nordisk regarding Icodec, a once-weekly basal insulin for the treatment of diabetes

DrFirst and Bizmatic Partner to Improve Medication Adherence

UCL launches UK’s first deep brain stimulation study in children with rare epilepsy

A Framework for Adding Software to Drug Labels: Q&A with Marty Culjat

Despite the powerful computing power, AI’s role in pharma remains plagued by challenges

Share This Article
Previous Article An inside look: Payments as a service
Next Article Roaring Kitty sued over GameStop ‘pump and dump’ allegations – Investorempires.com
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

5 fintech trends that will shake up Singapore in 2025
Fintech
Indonesia’s OJK issues new regulations on alternative credit scoring
Fintech
Donald Trump signs executive orders on trade on his first day in office
Manufacturing
Fifth Third expands branch network and doubles technology capabilities
Banking